. . . and ergot-derived dopamine agonists . . .

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1209, 2008-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Link Between Non-Ergot-Derived Dopamine Agonists and Heart Failure: How Strong Is It?

The Consultant Pharmacist, Vol. 30, Iss. 3, 2015-03 ,pp. : 136-140

American Society of Consultant Pharmacists

Access to resources Recommend Favorite

Pramipexole Safely Replaces Ergot Dopamine Agonists with either Rapid or Slow Switching

By Takahashi H Nogawa S Tachibana H Kawamura J Abe T Ogino Y Kashihara K Hamada T Kowa H

The Journal of International Medical Research, Vol. 36, Iss. 1, 2008-01 ,pp. : 106-114

Field House Publishing

Access to resources Recommend Favorite

Synthetic dopamine agonists

By Calne Donald B

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 4, 2002-04 ,pp. : 363-364

Informa Healthcare

Access to resources Recommend Favorite

Prevention of OHSS – dopamine agonists

By Busso Cristiano E Garcia-Velasco Juan Gomez Raúl Álvarez Claudio Simón Carlos Pellicer Antonio

Reproductive BioMedicine Online, Vol. 19, Iss. 1, 2009-07 ,pp. : 43-51

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Dopamine D3 agonists

By Emilien Gérard Durlach Cécile Aveaux Dominique Maloteaux Jean-Marie

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 11, 2001-11 ,pp. : 1713-1728

Informa Healthcare

Access to resources Recommend Favorite